Tanzanija - engleski - Tanzania Medicinces & Medical Devices Authority

sanofi pasteur, kenya - attenuated yellow fever - freeze dried powder for injection single dose - 17 d/ab 237 > 1000 ld50/05 ml

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer hydrochloride -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer hydrochloride -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - lixisenatide -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - teriflunomide -

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - neisseria meningitidis group a polysaccharide 50ug; neisseria meningitidis group c polysaccharide 50ug; neisseria meningitidis group w135 polysaccharide 50ug; neisseria meningitidis group y polysaccharide 50ug - injection with diluent - 0.5 ml - active: neisseria meningitidis group a polysaccharide 50ug neisseria meningitidis group c polysaccharide 50ug neisseria meningitidis group w135 polysaccharide 50ug neisseria meningitidis group y polysaccharide 50ug excipient: lactose monohydrate sodium chloride purified water - menomune® acyw-135 is indicated for active immunisation of adults and children older than 2 years against disease caused by neisseria meningitidis groups a, c, y and w-135, the major manifestation being meningococcal meningitis. vaccination may be considered for the following individuals: · travellers to countries recognised as having highly endemic or epidemic disease. · control of epidemics of infection caused by neisseria meningitidis groups a, c, y and w-135 in confined communities. · individuals at particular high risk of acquiring meningococcal infection, including persons with anatomic or functional asplenia. · close contacts of persons with meningococcal disease due to groups a, c, y and w-135, as an adjunct to appropriate chemoprophylaxis.

Singapur - engleski - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - hepatitis a virus (gbm strain), inactivated - suspension, sterile - 160 i.u./0.5 ml